B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2017 – Clinical Trials, Pharmaceuticals Industries

The B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2017 Report has been published. It provides updated in 2018 year analysis of industries from Clinical Trials, Pharmaceuticals Markets.

B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2017

Summary:

The clinical trial report, 'B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2017' provides an overview of B-Cell Non-Hodgkin Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

  • The report provides a snapshot of the global clinical trials landscape – Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status – The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company – The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment – The Report provides enrollment trends for the past five years – Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy:

  • Assists in formulating key business strategies with regards to investment – Helps in identifying prominent locations for conducting clinical trials which saves time and cost – Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities – Supports understanding of trials count and enrollment trends by country in global therapeutics market – Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials – Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Read more and order at B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2017

Global and Chinese Pressure injector Industry – 2017 – Drug Delivery, Infusions and Injectables, Pharmaceuticals Industries

The Global and Chinese Pressure injector Industry – 2017 Report has been published. It provides updated in 2018 year analysis of industries from Drug Delivery, Infusions and Injectables, Pharmaceuticals Markets.

The 'Global and Chinese Pressure injector Industry – 2017' is a professional and in-depth study on the current state of the global Pressure injector industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pressure injector manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company.

Through the statistical analysis, the report depicts the global and Chinese total market of the Pressure injector industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2017-2022 market development trends of the Pressure injector industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

In the end, the report makes some important proposals for a new project of the Pressure injector Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 global and Chinese Pressure injector industry covering all important parameters.

PLEASE NOTE: This report will be completed after order and will take approximately 2-3 business days after the confirmation of payment.

Read more and order at Global and Chinese Pressure injector Industry – 2017

Bone Marrow Transplant Rejection – Pipeline Review, H1 2017 – Drugs by Therapeutic Area, Immune Disorders Drugs, Immunosuppressive Drugs, Pharmaceuticals Industries

The Bone Marrow Transplant Rejection – Pipeline Review, H1 2017 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Immune Disorders Drugs, Immunosuppressive Drugs, Pharmaceuticals Markets.

Bone Marrow Transplant Rejection – Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection – Pipeline Review, H1 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 26, 16, 1, 35, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 13 and 3 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

– The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
– The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

Reasons to Buy:

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read more and order at Bone Marrow Transplant Rejection – Pipeline Review, H1 2017

Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016 – Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Industries

The Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016 Report has been published. It provides updated in 2018 year analysis of industries from Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Markets.

Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016

Summary

Our clinical trial report, “Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016" provides an overview of Occlusive Arterial Disease (OAD) clinical trials scenario. This report provides top line data relating to the clinical trials on Occlusive Arterial Disease (OAD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

Read more and order at Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016

The 2018-2023 World Outlook for Vaccines and Toxiods for Human Use Excluding Allergens and Diagnostics – Biopharmaceuticals, Pharmaceuticals, Vaccines Industries

The The 2018-2023 World Outlook for Vaccines and Toxiods for Human Use Excluding Allergens and Diagnostics Report has been published. It provides updated in 2018 year analysis of industries from Biopharmaceuticals, Pharmaceuticals, Vaccines Markets.

This study covers the world outlook for vaccines and toxiods for human use excluding allergens and diagnostics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E., for vaccines and toxiods for human use excluding allergens and diagnostics. It also shows how the P.I.E. is divided across the world's regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

1.3 The Methodology

In order to estimate the latent demand for vaccines and toxiods for human use excluding allergens and diagnostics on a worldwide basis, I used a multi-stage approach. Before applying the approach, one needs a basic theory from which such estimates are created. In this case, I heavily rely on the use of certain basic economic assumptions. In particular, there is an assumption governing the shape and type of aggregate latent demand functions. Latent demand functions relate the income of a country, city, state, household, or individual to realized consumption. Latent demand (often realized as consumption when an industry is efficient), at any level of the value chain, takes place if an equilibrium is realized. For firms to serve a market, they must perceive a latent demand and be able to serve that demand at a minimal return. The single most important variable determining consumption, assuming latent demand exists, is income (or other financial resources at higher levels of the value chain). Other factors that can pivot or shape demand curves include external or exogenous shocks (i.e., business cycles), and or changes in utility for the product in question.

Ignoring, for the moment, exogenous shocks and variations in utility across countries, the aggregate relation between income and consumption has been a central theme in economics. The figure below concisely summarizes one aspect of problem. In the 1930s, John Meynard Keynes conjectured that as incomes rise, the average propensity to consume would fall. The average propensity to consume is the level of consumption divided by the level of income, or the slope of the line from the origin to the consumption function. He estimated this relationship empirically and found it to be true in the short-run (mostly based on cross-sectional data). The higher the income, the lower the average propensity to consume. This type of consumption function is shown as "B" in the figure below (note the rather flat slope of the curve). In the 1940s, another macroeconomist, Simon Kuznets, estimated long-run consumption functions which indicated that the marginal propensity to consume was rather constant (using time series data across countries). This type of consumption function is show as "B" in the figure below (note the higher slope and zero-zero intercept).

The average propensity to consume is constant. For a general overview of this subject area, see Principles of Macroeconomics by N. Gregory Mankiw, South-Western College Publishing; ISBN: 0030340594; 2nd edition (February 2002).

Is it declining or is it constant? A number of other economists, notably Franco Modigliani and Milton Friedman, in the 1950s (and Irving Fisher earlier), explained why the two functions were different using various assumptions on intertemporal budget constraints, savings, and wealth. The shorter the time horizon, the more consumption can depend on wealth (earned in previous years) and business cycles. In the long-run, however, the propensity to consume is more constant. Similarly, in the long-run, households, industries, or countries with no income eventually have no consumption (wealth is depleted). While the debate surrounding beliefs about how income and consumption are related and interesting, in this study a very particular school of thought is adopted. In particular, we are considering the latent demand for vaccines and toxiods for human use excluding allergens and diagnostics across some 190 countries. The smallest have fewer than 10,000 inhabitants. I assume that all of these counties fall along a "long-run" aggregate consumption function. This long-run function applies despite some of these countries having wealth; current income dominates the latent demand for vaccines and toxiods for human use excluding allergens and diagnostics. So, latent demand in the long-run has a zero intercept. However, I allow firms to have different propensities to consume (including being on consumption functions with differing slopes, which can account for differences in industrial organization, and end-user preferences).

Given this overriding philosophy, I will now describe the methodology used to create the latent demand estimates for vaccines and toxiods for human use excluding allergens and diagnostics. Since this methodology applies to a large number of categories, the rather academic discussion below is general and can be applied to a wide variety of categories, not just vaccines and toxiods for human use excluding allergens and diagnostics.

1.3.1 Step 1. Product Definition And Data Collection

Any study of latent demand across countries requires that some standard be established to define "efficiently served". Having implemented various alternatives and matched these with market outcomes, I have found that the optimal approach is to assume that certain key countries are more likely to be at or near efficiency than others. These countries are given greater weight than others in the estimation of latent demand compared to other countries for which no known data are available. Of the many alternatives, I have found the assumption that the world’s highest aggregate income and highest income-per-capita markets reflect the best standards for “efficiency”. High aggregate income alone is not sufficient (i.e., China has high aggregate income, but low income per capita and cannot be assumed to be efficient). Aggregate income can be operationalized in a number of ways, including gross domestic product (for industrial categories), or total disposable income (for household categories; population times average income per capita, or number of households times average household income per capita). Brunei, Nauru, Kuwait, and Lichtenstein are examples of countries with high income per capita, but not assumed to be efficient, given low aggregate level of income (or gross domestic product); these countries have, however, high incomes per capita but may not benefit from the efficiencies derived from economies of scale associated with large economies. Only countries with high income per capita and large aggregate income are assumed efficient. This greatly restricts the pool of countries to those in the OECD (Organization for Economic Cooperation and Development), like the United States, or the United Kingdom (which were earlier than other large OECD economies to liberalize their markets).

The selection of countries is further reduced by the fact that not all countries in the OECD report have industry revenues at the category level. Countries that typically have ample data at the aggregate level that meet the efficiency criteria include the United States, the United Kingdom, and in some cases France and Germany.
Is it declining or is it constant? A number of other economists, notably Franco Modigliani and Milton Friedman, in the 1950s (and Irving Fisher earlier), explained why the two functions were different using various assumptions on intertemporal budget constraints, savings, and wealth. The shorter the time horizon, the more consumption can depend on wealth (earned in previous years) and business cycles. In the long-run, however, the propensity to consume is more constant. Similarly, in the long-run, households, industries, or countries with no income eventually have no consumption (wealth is depleted). While the debate surrounding beliefs about how income and consumption are related and interesting, in this study a very particular school of thought is adopted. In particular, we are considering the latent demand for vaccines and toxiods for human use excluding allergens and diagnostics across some 190 countries. The smallest have fewer than 10,000 inhabitants. I assume that all of these counties fall along a "long-run" aggregate consumption function. This long-run function applies despite some of these countries having wealth; current income dominates the latent demand for vaccines and toxiods for human use excluding allergens and diagnostics. So, latent demand in the long-run has a zero intercept. However, I allow firms to have different propensities to consume (including being on consumption functions with differing slopes, which can account for differences in industrial organization, and end-user preferences).Given this overriding philosophy, I will now describe the methodology used to create the latent demand estimates for vaccines and toxiods for human use excluding allergens and diagnostics. Since this methodology applies to a large number of categories, the rather academic discussion below is general and can be applied to a wide variety of categories, not just vaccines and toxiods for human use excluding allergens and diagnostics.

1.3.1 Step 1. Product Definition And Data Collection

Any study of latent demand across countries requires that some standard be established to define "efficiently served". Having implemented various alternatives and matched these with market outcomes, I have found that the optimal approach is to assume that certain key countries are more likely to be at or near efficiency than others. These countries are given greater weight than others in the estimation of latent demand compared to other countries for which no known data are available. Of the many alternatives, I have found the assumption that the world’s highest aggregate income and highest income-per-capita markets reflect the best standards for “efficiency”. High aggregate income alone is not sufficient (i.e., China has high aggregate income, but low income per capita and cannot be assumed to be efficient). Aggregate income can be operationalized in a number of ways, including gross domestic product (for industrial categories), or total disposable income (for household categories; population times average income per capita, or number of households times average household income per capita). Brunei, Nauru, Kuwait, and Lichtenstein are examples of countries with high income per capita, but not assumed to be efficient, given low aggregate level of income (or gross domestic product); these countries have, however, high incomes per capita but may not benefit from the efficiencies derived from economies of scale associated with large economies. Only countries with high income per capita and large aggregate income are assumed efficient. This greatly restricts the pool of countries to those in the OECD (Organization for Economic Cooperation and Development), like the United States, or the United Kingdom (which were earlier than other large OECD economies to liberalize their markets).The selection of countries is further reduced by the fact that not all countries in the OECD report have industry revenues at the category level. Countries that typically have ample data at the aggregate level that meet the efficiency criteria include the United States, the United Kingdom, and in some cases France and Germany.Latent demand is therefore estimated using data collected for relatively efficient markets from independent data sources (e.g. Euromonitor, Mintel, Thomson Financial Services, the U.S. Industrial Outlook, the World Resources Institute, the Organization for Economic Cooperation and Development, various agencies from the United Nations, industry trade associations, the International Monetary Fund, and the World Bank). Depending on original data sources used, the definition of "vaccines and toxiods for human use excluding allergens and diagnostics" is established. In the case of this report, the data were reported at the aggregate level, with no further breakdown or definition. In other words, any potential products and/or services that might be incorporated within vaccines and toxiods for human use excluding allergens and diagnostics fall under this category. Public sources rarely report data at the disaggregated level in order to protect private information from individual firms that might dominate a specific product-market. These sources will therefore aggregate across components of a category and report only the aggregate to the public. While private data are certainly available, this report only relies on public data at the aggregate level without reliance on the summation of various category components. In other words, this report does not aggregate a number of components to arrive at the "whole". Rather, it starts with the "whole", and estimates the whole for all countries and the world at large (without needing to know the specific parts that went into the whole in the first place).Given this caveat, this study covers "vaccines and toxiods for human use excluding allergens and diagnostics" as defined by the North American Industrial Classification system or NAICS (pronounced "nakes"). For a complete definition of vaccines and toxiods for human use excluding allergens and diagnostics, please refer to the Web site:[external URL]
The NAICS code for vaccines and toxiods for human use excluding allergens and diagnostics is 32541441. It is for this definition of vaccines and toxiods for human use excluding allergens and diagnostics that the aggregate latent demand estimates are derived. "Vaccines and toxiods for human use excluding allergens and diagnostics" is specifically defined as follows:
32541441Biological products, excluding diagnostic, vaccines, toxiods, excluding allergens, for human use3254144100Biological products, excluding diagnostic, vaccines, toxiods, excluding allergens, for human use 325414411Veterinary vaccines325414415Bacterins, toxoids, and other antigens for active immunizationThis report was prepared from a variety of sources including excerpts from documents and official reports or databases published by the World Bank, the U.S. Department of Commerce, the U.S. State Department, various national agencies, the International Monetary Fund, the Central Intelligence Agency, various agencies from the United Nations (e.g. ILO, ITU, UNDP, etc.), and non-governmental sources and various public sources cited in the trade press.

1.3.2 Step 2. Filtering And Smoothing

Based on the aggregate view of vaccines and toxiods for human use excluding allergens and diagnostics as defined above, data were then collected for as many similar countries as possible for that same definition, at the same level of the value chain. This generates a convenience sample of countries from which comparable figures are available. If the series in question do not reflect the same accounting period, then adjustments are made. In order to eliminate short-term effects of business cycles, the series are smoothed using a 2-year moving average weighting scheme (longer weighting schemes do not substantially change the results). If data are available for a country, but these reflect short-run aberrations due to exogenous shocks (such as would be the case of beef sales in a country stricken with foot and mouth disease), these observations were dropped or "filtered" from the analysis.

1.3.3 Step 3. Filling In Missing Values

In some cases, data are available for countries on a sporadic basis. In other cases, data from a country may be available for only one year. From a Bayesian perspective, these observations should be given the greatest weight in estimating missing years. Assuming that other factors are held constant, the missing years are extrapolated using changes and growth in aggregate national income. Based on the overriding philosophy of a long-run consumption function (defined earlier), countries which have missing data for any given year are estimated based on historical dynamics of aggregate income for that country.

1.3.4 Step 4. Varying Parameter, Non-Linear Estimation

Given the data available from the first three steps, the latent demand in additional countries is estimated using a "varying-parameter cross-sectionally pooled time series model".

The interested reader can find longer discussions of this type of modeling in Studies in Global Econometrics (Advanced Studies in Theoretical and Applied Econometrics V. 30), by Henri Theil, et al., Kluwer Academic Publishers; ISBN: 0792336607; (June 1996), and in Principles of Econometrics, by Henri Theil John Wiley & Sons; ISBN: 0471858455; (December 1971), and in Econometric Models and Economic Forecasts by Robert S. Pindyck, Daniel L. Rubinfeld McGraw Hill Text; ISBN: 0070500983; 3rd edition (December 1991). Simply stated, the effect of income on latent demand is assumed to be constant across countries unless there is empirical evidence to suggest that this effect varies (i.e., the slope of the income effect is not necessarily the same for all countries). This assumption applies across countries along the aggregate consumption function, but also over time (i.e., not all countries are perceived to have the same income growth prospects over time and this effect can vary from country to country as well). Another way of looking at this is to say that latent demand for vaccines and toxiods for human use excluding allergens and diagnostics is more likely to be similar across countries that have similar characteristics in terms of economic development (i.e., African countries will have similar latent demand structures controlling for the income variation across the pool of African countries). This approach is useful across countries for which some notion of non-linearity exists in the aggregate cross-country consumption function. For some categories, however, the reader must realize that the numbers will reflect a country’s contribution to global latent demand and may never be realized in the form of local sales. For certain country-category combinations this will result in what at first glance will be odd results. For example, the latent demand for the category "space vehicles" will exist for Togo even though they have no space program. The assumption is that if the economies in these countries did not exist, the world aggregate for these categories would be lower. The share attributed to these countries is based on a proportion of their income (however small) being used to consume the category in question (i.e., perhaps via resellers).

1.3.5 Step 5. Fixed-Parameter Linear Estimation

Nonlinearities are assumed in cases where filtered data exist along the aggregate consumption function. Because the world consists of more than 200 countries, there will always be those countries, especially toward the bottom of the consumption function, where non-linear estimation is simply not possible. For these countries, equilibrium latent demand is assumed to be perfectly parametric and not a function of wealth (i.e., a country’s stock of income), but a function of current income (a country’s flow of income). In the long run, if a country has no current income, the latent demand for vaccines and toxiods for human use excluding allergens and diagnostics is assumed to approach zero. The assumption is that wealth stocks fall rapidly to zero if flow income falls to zero (i.e., countries which earn low levels of income will not use their savings, in the long run, to demand vaccines and toxiods for human use excluding allergens and diagnostics). In a graphical sense, for low-income countries, latent demand approaches zero in a parametric linear fashion with a zero-zero intercept. In this stage of the estimation procedure, low-income countries are assumed to have a latent demand proportional to their income, based on the country closest to it on the aggregate consumption function.

1.3.6 Step 6. Aggregation And Benchmarking

Based on the models described in Chapter 1, latent demand figures are estimated for all countries of the world, including for the smallest economies. These are then aggregated to get world totals and regional totals. To make the numbers more meaningful, regional and global demand averages are presented. Figures are rounded, so minor inconsistencies may exist across tables.

1.3.7 Step 7. Latent Demand Density: Allocating Across Cities

With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report also covers the world’s top 2,000 cities. The purpose is to understand the density of demand within a country and the extent to which a city might be used as a point of distribution within its region. From an economic perspective, however, a city does not represent a population within rigid geographical boundaries. To an economist or strategic planner, a city represents an area of dominant influence over markets in adjacent areas. This influence varies from one industry to another, but also from one period of time to another.

Similar to country-level data, the reader needs to realize that latent demand allocated to a city may or may not represent real sales. For many items, latent demand is clearly observable in sales, as in the case for food or housing items. Consider, again, the category "satellite launch vehicles." Clearly, there are no launch pads in most cities of the world. However, the core benefit of the vehicles (e.g. telecommunications, etc.) is "consumed" by residents or industries within the world's cities. Without certain cities, in other words, the world market for satellite launch vehicles would be lower for the world in general. One needs to allocate, therefore, a portion of the worldwide economic demand for launch vehicles to regions, countries, and cities. This report takes the broader definition and considers, therefore, a city as a part of the global market. I allocate latent demand across areas of dominant influence based on the relative economic importance of cities within its home country, within its region, and across the world total. Not all cities are estimated within each country as demand may be allocated to adjacent areas of influence. Since some cities have higher economic wealth than others within the same country, a city’s population is not generally used to allocate latent demand. Rather, the level of economic activity of the city is used vis-à-vis others.

Read more and order at The 2018-2023 World Outlook for Vaccines and Toxiods for Human Use Excluding Allergens and Diagnostics

Profiles of Drug Substances, Excipients and Related Methodology, Vol 32 – Pharmaceutical Intermediates, Pharmaceuticals Industries

The Profiles of Drug Substances, Excipients and Related Methodology, Vol 32 Report has been published. It provides updated in 2018 year analysis of industries from Pharmaceutical Intermediates, Pharmaceuticals Markets.

Whilst following in the footsteps of previous volumes by presenting comprehensive reviews of drug substances and additional materials, this title also heralds a significant expansion of the scope of the series. Traditional contributions are now augmented by publication of critical review chapters that summarize information related to the characterization of drug substances and excipients. This change meets the needs of the pharmaceutical community and allows the development of a timely vehicle for publishing review materials on this topic. While offering comprehensive and specialised chapters, Profiles of Drug Substances, Excipients and Related Methodology, Volume 32 also presents a methodology review article on the validation of chromatographic methods of analysis, as well as a summary of the publications in 2004 that dealt with polymorphism and solvatomorphism.

  • Presents comprehensive reviews covering all aspects of drug development and formulation of drugs
  • Now encompassing critical review chapters
  • Meets the information needs of the drug development community

Read more and order at Profiles of Drug Substances, Excipients and Related Methodology, Vol 32

Microbe – Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals Industries

The Microbe Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals Markets.

Microbe, a brand–new, general microbiology textbook intended for upper–division undergraduate and beginning graduate courses, is an exciting introduction to the world of microbes. With a distinct ecological and evolutionary orientation, Microbe invites readers to partake of the most current advances in the field. Written by prominent scientists with practical teaching, textbook writing, and research experience, this new textbook will engage students in the learning process with its clear, reader–friendly style and unique perspective of the field. Microbe is paradigm–driven rather than fact–driven. Key concepts are illustrated by inspiring examples that convey the excitement of the field. This is not a compendium of facts, but rather a textbook in the older, traditional sense: a book that can be used for studying rather than for looking up factual information. The book is divided into seven sections covering the most pertinent information related to the study of microbes, including microbial activity; structure and function; growth, inheritance, physiology, and diversity; and biological interactions. Each chapter concludes with thought–provoking study questions, for which answers are listed in the back of the book. Microbe is accompanied by a dedicated Web site featuring links to additional information and animation and video clips related to material covered in the book. Sidebars throughout the text guide readers to designated links that are easily accessed through the Microbe homepage. The Web site will be monitored and updated regularly by the authors.

Read more and order at Microbe

Cystic Fibrosis, An Issue of Clinics in Chest Medicine. The Clinics: Internal Medicine 37-1 – Drugs by Therapeutic Area, Pharmaceuticals, Respiratory Drugs Industries

The Cystic Fibrosis, An Issue of Clinics in Chest Medicine. The Clinics: Internal Medicine 37-1 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Pharmaceuticals, Respiratory Drugs Markets.

Dr. Jon Koff has assembled and expert team of authors of the topic of Cystic Fibrosis. Articles include: Epidemiology and Pathobiology, Genetics and genetic medicine in Cystic Fibrosis, Innate and Adaptive Immunity in Cystic Fibrosis, Microbiome in Cystic Fibrosis, Diagnostic Testing in Cystic Fibrosis, Treating Pseudomonas in Cystic Fibrosis, Diagnosis of Adult Patients with Cystic Fibrosis, Transition from Pediatrics to Adult Care, Lung Transplant in Cystic Fibrosis, and more!

Read more and order at Cystic Fibrosis, An Issue of Clinics in Chest Medicine. The Clinics: Internal Medicine 37-1

Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2016 – Drug Delivery, Pharmaceuticals, Transdermal and Transmucosal Drug Delivery Industries

The Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2016 Report has been published. It provides updated in 2018 year analysis of industries from Drug Delivery, Pharmaceuticals, Transdermal and Transmucosal Drug Delivery Markets.

Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2016

Summary

the author's Medical Devices sector report, “Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2016" provides an overview of Transdermal Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

– Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

– Extensive coverage of the Transdermal Drug Delivery under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Transdermal Drug Delivery and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment/industry

Reasons to buy

The report enables you to:

– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Transdermal Drug Delivery under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Read more and order at Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2016

Burkitt Lymphoma Global Clinical Trials Review, H1, 2017 – Clinical Trials, Pharmaceuticals Industries

The Burkitt Lymphoma Global Clinical Trials Review, H1, 2017 Report has been published. It provides updated in 2018 year analysis of industries from Clinical Trials, Pharmaceuticals Markets.

Burkitt Lymphoma Global Clinical Trials Review, H1, 2017

Summary

The clinical trial report, “Burkitt Lymphoma Global Clinical Trials Review, H1, 2017" provides an overview of Burkitt Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Burkitt Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the author’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Read more and order at Burkitt Lymphoma Global Clinical Trials Review, H1, 2017